Needham Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $52
Rocket Pharmaceuticals, Inc. +2.64% Pre
Rocket Pharmaceuticals, Inc. RCKT | 17.49 17.49 | +2.64% 0.00% Pre |
Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:
RCKT) with a Buy and lowers the price target from $53 to $52.